A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Verus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin +Etoposide.

Trial Profile

A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Verus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin +Etoposide.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Meclinertant (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SESAME
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Dec 2008 Actual patient number (432) added as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Actual end date changed from Apr 2006 to Mar 2006 as reported by Clinicaltrials.gov.
    • 13 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top